| Autor: |
Holland A; University of Bristol, Oakfield Grove, Clifton, Bristol BS8 2BN, UK adam.holland@bristol.ac.uk., Brothers TD; These authors contributed equally and are listed in alphabetical order.; Division of General Internal Medicine, Department of Medicine, Dalhousie University, Halifax, NS, Canada., Lewer D; These authors contributed equally and are listed in alphabetical order.; Bradford Institute for Health Research, Bradford Institute for Health Research Temple Bank House, Bradford Royal Infirmary, Bradford, UK., Maynard OM; These authors contributed equally and are listed in alphabetical order.; University of Bristol, School of Psychological Science, Clifton, Bristol, UK., Southwell M; These authors contributed equally and are listed in alphabetical order.; European Network of People who Use Drugs. |
| Abstrakt: |
Competing Interests: Competing interests: The BMJ has judged that there are no disqualifying financial ties to commercial companies. The authors declare the following other interests: AH is doing a PhD funded by the Medical Research Council (grants MR/W006308/1 and MR/X018636/1), is co-chair of the Faculty of Public Health Drugs Special Interest Group, volunteers for the Loop (a drug checking organisation), is a member of the Drug Science Enhanced Harm Reduction Working Group, and has worked on various projects advocating for the decriminalisation of drug possession and harm reduction interventions; TDB is employed as a salaried medical resident (trainee) by Nova Scotia Health and Dalhousie University, holds a grant from the Canadian Institutes of Health Research (FRN 185469) focused on injection drug use associated infective endocarditis, and practices addiction medicine and prescribes safer supply medications, but does not receive any financial benefit from doing so; MS is project executive for the European Network of People who Use Drugs (EuroNPUD); EuroNPUD has received unrestricted educational grants from Camurus and Indivior to deliver a client resource on opioid agonist maintenance treatment and to run an advocacy event at the United Nations Commission on Narcotic Drugs in March 2023, respectively; EuroNPUD has also received a grant from ViiV Europe, the donor arm of the HIV pharmaceutical company. Further details of The BMJ policy on financial interests is here: https://www.bmj.com/sites/default/files/attachments/resources/2016/03/16-current-bmj-education-coi-form.pdf." |
